Cosmetic Surveillance: An update and comprehensive Review
Surveillance has recently been expanded to include the safety of herbal and cosmetic products. A new phrase has emerged characterizing industry monitoring known as “Kosmetonadzor” to ensure the safety of cosmetic products. Wigan (1997) was the first in the literature to use the term to refer to the safety management of cosmetic products. It is now recognized as a public health concept worldwide.
As there is no systematic reporting system, side effects or side effects of cosmetics are relatively insignificant or overlooked. There is a follow-up management system for preparation. In India, market surveillance is usually focused on drug side effects. As a result, more emphasis has been placed on medical devices, blood products, biologics, natural products, and special diets, and less on related side effects. To sum up, Cosmetology refers to the monitoring of cosmetic products that have recently entered the market.
Cosmetic surveillance is a new approach to regulating the safety of cosmetic products. It is an important component of public health initiatives. As post-sale surveillance of cosmetics becomes more and more common worldwide, malfunctions in these items can be detected and corrected, so safety can be achieved. Physicians Family doctors and general practitioners play an important role in detecting ADRs caused by cosmetic items and, as a result, urge patients to report ADRs. Raising awareness of this new notion will be an important contribution to global public health.
In general, the Cosmetovigilance system can avoid both significant and minor adverse effects. Because the notification procedure is critical to the system, healthcare workers must be taught and supported as part of the Cosmetovigilance feedback system. Some regulation modifications are required to keep up with Turkey's developing cosmetics business.
In general, cosmetic monitoring systems can prevent both serious and minor side effects. As the reporting process is a key element of the system, medical professionals must be educated and supported in terms of cosmetic oversight within the feedback system. Some regulatory updates are needed to keep pace with the changing Turkish cosmetics market.
2. Moretti U, Velo G. Cosmetovigilance: the “beautiful” risk. Drug Saf. 2008;31(5):437-9.
3. Ferreira M, Matos A, Couras A, Marto J, Ribeiro H. Overview of Cosmetic Regulatory Frameworks around the World. Cosmetics. 2022 Jun 30;9(4):72.
4. Jyrwa S, Sebastian J, Shastry V. Cosmetovigilance in a tertiary care hospital: A prospective observational study. J Cosmet Dermatol. 2021 Mar 17;20(3):804-11.
5. Vigan M, Castelain F. Cosmetovigilance: definition, regulation and use “in practice.” European Journal of Dermatology. 2014 Nov;24(6):643-9.
6. Epstein HA. How dirty are the dirty dozen ingredients in cosmetics? Skinmed. 2012;10(5):305-8.
7. Straetemans M, Katz LM, Belson M. Adverse reactions after permanent-makeup procedures. N Engl J Med. 2007 Jun 28;356(26):2753.
8. Lindberg M, Tammela M, Boström A, Fischer T, Inerot A, Sundberg K, et al. Are adverse skin reactions to cosmetics underestimated in the clinical assessment of contact dermatitis? A prospective study among 1075 patients attending Swedish patch test clinics. Acta Derm Venereol. 2004;84(4):291-5.
9. Lucca JM, Joseph R, Hussain Al Kubaish Z, Mohammad Al-Maskeen S, Ali Alokaili Z. An observational study on adverse reactions of cosmetics: The need of practice the Cosmetovigilance system. Saudi Pharmaceutical Journal. 2020 Jun;28(6):746-53.
10. Henkler F, Tralau T, Tentschert J, Kneuer C, Haase A, Platzek T, et al. Risk assessment of nanomaterials in cosmetics: a European union perspective. Arch Toxicol. 2012 Nov 2;86(11):1641-6.
11. Toklu H, Antigua A, Lewis V, Reynolds M, Jones J. Cosmetovigilance: A review of the current literature. J Family Med Prim Care. 2019;8(5):1540.
12. Pistollato F, Madia F, Corvi R, Munn S, Grignard E, Paini A, et al. Current EU regulatory requirements for the assessment of chemicals and cosmetic products: challenges and opportunities for introducing new approach methodologies. Arch Toxicol. 2021 Jun 13;95(6):1867-97.
13. Sarma P, Kumar H, Medhi B. Cosmetovigilance in India: Need of the day. Indian J Pharmacol. 2017;49(5):341-3.
14. Applications Forms for all types of Cosmetics under Cosmetics Rules 2020 [Internet]. [cited 2023 Mar 06]. Available from:
15. Sarma P, Kumar H, Medhi B. Cosmetovigilance in India: Need of the day. Indian J Pharmacol. 2017;49(5):341-3.
16. 2013/674/EU: Commission Implementing Decision of 25 November 2013 on Guidelines on Annex I to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products Text with EEA relevance; 2013 Nov.
17. Renner G, Audebert F, Burfeindt J, Calvet B, Caratas-Perifan M, Leal M, et al. Cosmetics Europe Guidelines on the Management of Undesirable Effects and Reporting of Serious Undesirable Effects from Cosmetics in the European Union. Cosmetics. 2017 Jan 3;4(1):1.
18. Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, et al. ECVAM’s Response to the Changing Political Environment for Alternatives: Consequences of the European Union Chemicals and Cosmetics Policies. Alternatives to Laboratory Animals. 2003 Sep 9;31(5):473-81.
19. Nagarnaik M, Sarjoshi A, Linge P, Bhore S, Pandya G. A Microbial Study of Some Cosmetics and Raw Materials Used in Personal Care Products in Urban Area. Research Journal of Topical and Cosmetic Sciences. 2015;6(1):48.
20. Bashir A, Lambert P. Microbiological study of used cosmetic products: highlighting possible impact on consumer health. J Appl Microbiol. 2020 Feb;128(2):598-605.
21. Halla N, Fernandes IP, Heleno SA, Costa P, Boucherit-Otmani Z, Boucherit K, et al. Cosmetics Preservation: A Review on Present Strategies. Molecules. 2018 Jun 28;23(7).
22. Bilal AI, Tilahun Z, Osman ED, Mulugeta A, Shekabdulahi M, Berhe DF. Cosmetics Use-Related Adverse Events and Determinants Among Jigjiga Town Residents, Eastern Ethiopia. Dermatol Ther (Heidelb). 2017 Mar;7(1):143-53.
23. Cornell E, Kwa M, Paller AS, Xu S. Adverse events reported to the Food and Drug Administration from 2004 to 2016 for cosmetics and personal care products marketed to newborns and infants. Pediatr Dermatol. 2018 Mar;35(2):225-9.
24. Kwa M, Welty LJ, Xu S. Adverse Events Reported to the US Food and Drug Administration for Cosmetics and Personal Care Products. JAMA Intern Med. 2017 Aug 1;177(8):1202.
25. Jicheng Y, Yuqi Z, Yanqi Y, Davis R, Wujin S, Frances L, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles for rapid glucose-responsive insulin delivery. Front Bioeng Biotechnol. 2016;4.
26. Altıokka İ, Üner M. Safety in Cosmetics and Cosmetovigilance, Current Regulations in Türkiye. Turk J Pharm Sci. 2022 Oct 31;19(5):610-7.
27. Griffiths D, Mullock A. Cosmetic Surgery: Regulatory Challenges in a Global Beauty Market. Health Care Analysis. 2018 Sep 28;26(3):220-34.
28. Cáceres Guevara PN, Lang KL, Novoa MA. Cosmetovigilancia: un estudio de alcance. Revista Colombiana de Ciencias Químico-Farmacéuticas. 2016 Oct 4;45(2):305.
29. Jairoun AA, Al-Hemyari SS, Shahwan M, Zyoud SH. Analysis and Quantification of Alkyl (C12-22) Trimethyl Ammonium Chloride Content in Cosmetics: Regulatory Compliance Gap Analysis. Cosmetics. 2021 Nov 3;8(4):103.
30. Arivazhahan A, Kunder SK. Adverse Effects and Pharmacovigilance. In: Introduction to Basics of Pharmacology and Toxicology. Singapore: Springer Singapore; 2019. p. 177-96.
31. Renner G, Audebert F, Burfeindt J, Calvet B, Caratas-Perifan M, Leal M, et al. Cosmetics Europe Guidelines on the Management of Undesirable Effects and Reporting of Serious Undesirable Effects from Cosmetics in the European Union. Cosmetics. 2017 Jan 3;4(1):1.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM